Overview

CT 327 in the Treatment of Psoriasis Vulgaris

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study will look at how safe and effective, a novel agent, CT 327 cream is in treating patients with mild to moderate psoriasis vulgaris (PV). Patients will be treated twice daily for 8 weeks on specific lesions of PV and safety and symptoms of PV will be assessed throughout the treatment period.
Phase:
Phase 2
Details
Lead Sponsor:
Creabilis SA